Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial

Core Insights - Avant Technologies Inc. and Ainnova Tech, Inc. are collaborating on a clinical trial for the Vision AI platform aimed at early detection of diabetic retinopathy [1][4] - Ainnova is refining its patient recruitment strategy to include approximately 1,000 multiethnic patients, focusing on community clinics rather than specialized centers [2][3] - The partnership with Fortrea, a recognized Contract Research Organization, is expected to enhance the quality and efficiency of the clinical study [4][5] Company Overview - Avant Technologies Inc. is an emerging technology company focused on healthcare solutions utilizing artificial intelligence and biotechnology [7] - Ainnova Tech, Inc. is a healthtech startup dedicated to leveraging AI for early disease detection, with a specific focus on preventing blindness related to diabetes [6] Clinical Trial Details - The clinical study will take place at 8-10 sites across the U.S., targeting a diverse patient population to ensure the data reflects real-world scenarios [2][3] - The study's design aims to support the FDA 510(k) submission, which is crucial for regulatory approval and market entry [4][5] Strategic Importance - The success of the clinical trial is vital for Ainnova's technology portfolio, particularly for entering the U.S. market, which presents significant commercial potential [5]